U.S. Capitol Building illuminated at twilight

Policy & Advocacy

We Don’t Just Meet the Standard. We Help Write It.

NWP Healthcare operates at the intersection of clinical science, legal admissibility, and federal policy. With decades of Washington, D.C. insider experience, we shape the rules that govern how biomarker evidence enters the courtroom.

Request a Policy Briefing View the Science

Washington, D.C. Insiders

Why NWP Is Uniquely Positioned

Our leadership team brings decades of experience across government agencies, the U.S. Department of Defense, military medical institutions, and Capitol Hill. We do not simply respond to evidentiary standards. We participate in building them.

That means our biomarker protocols are designed from the ground up to satisfy Daubert reliability requirements, because we understand exactly what courts, regulators, and policymakers demand.

Federal Policy Access

Direct engagement with regulatory bodies, defense agencies, and legislative stakeholders.

Daubert-First Design

Every protocol built to withstand judicial scrutiny on reliability, fit, and methodology.

Cross-Sector Credibility

Affiliations spanning Walter Reed, George Washington University, and the Uniformed Services University.

250+ Publications

Peer-reviewed work in human performance, public safety, health care, and consumer protection.

Daubert Admissibility — 2026 Update

Biomarker Risk Assessment

Under the Daubert standard, courts scrutinize scientific testimony for reliability and relevance. Here is where each marker stands.

GFAP

Current Landscape

FDA-cleared (2018–2024), ≥95% sensitivity, used in ER triage and military protocols. Already admitted in recent TBI cases.

NWP Advantage

NWP deploys FDA-cleared assays within a patented evidence system that documents every QC threshold, calibration log, and chain-of-custody step. Our protocols mirror what courts have already accepted and what we help shape at the federal level.

Patented end-to-end workflow built for courtroom scrutiny from day one.

NfL

Current Landscape

Extensive peer-reviewed research, validated assays (SIMOA), growing expert consensus. No FDA clearance for TBI yet, but strong foundation.

NWP Advantage

NWP pairs NfL with GFAP in a multi-marker panel, strengthening evidentiary weight through corroboration. Standardized collection timing, processing controls, and longitudinal baselines neutralize the two main attack vectors: novelty and interpretive variance.

Multi-marker panel strategy turns an emerging biomarker into defensible evidence.

APOE

Current Landscape

Genotyping is analytically reliable. Admissible for prognosis and susceptibility context; limited for direct causation claims.

NWP Advantage

NWP positions APOE strictly as a risk-context marker, never standalone causation. Reports frame APOE within published meta-analyses on post-TBI vulnerability, keeping testimony within the bounds courts accept.

Structured interpretation framework prevents overreach that triggers exclusion.

p-Tau 217

Current Landscape

Primarily validated for Alzheimer’s disease. TBI application is research-stage. Likely challenged if used for trauma-specific causation in 2026.

NWP Advantage

NWP includes p-Tau 217 only as a corroborative signal within a full panel, never as a standalone diagnostic claim. Paired with GFAP and NfL, it strengthens the severity narrative without carrying the evidentiary burden alone—the same approach that succeeded in the $831M Mendez verdict.

Panel architecture lets cutting-edge science enter the courtroom without carrying solo risk.

Decision-Grade Evidence

What Makes Our Biomarker Evidence Defensible

The evidentiary value is never just the number. It is the combination of standardized workflow, validated interpretation, and longitudinal consistency.

End-to-End

Tracked

Chain-of-Custody

Every sample transfer logged from draw to lab. Without it, evidence may be excluded.

5-Point

Check System

QC & Integrity

Hemolysis, volume, and stability checks on every specimen. Anomalies trigger documented exceptions.

Zero

Blind Spots

Immutable Audit Trails

Digital logs of when and by whom data were accessed or reports generated.

One

Unified Format

Standard Reporting

Consistent format and language so results are unambiguous and reproducible.

Built-In

Compliance

Method Validation

Assay methods and interpretive algorithms fully documented to FDA/CLIA standards.

Published

Benchmarks

Known Error Rates

Published sensitivity, specificity, and confidence bands satisfy Daubert reliability criteria.

Patented Evidence System

A System, Not Simply a Test

NWP delivers a standardized, end-to-end workflow that produces reportable findings and supports repeat measurement across three output dimensions.

Pre-Analytical Controls

Standardized collection tubes

Handling & processing time windows

Hemolysis checks

Identity & custody verification

System Outputs

Determination Support

Objective indicators consistent with injury signal presence or absence.

Severity Stratification

Graded outputs aligned to severity bands with confidence framing.

Trajectory Tracking

Longitudinal trend reporting to evaluate persistence, recovery, or progression.

Courtroom Precedent

Where Biomarkers Have Already Won

Between 2023 and 2026, TBI biomarker evidence has been successfully introduced in U.S. courts, driving significantly higher awards.

2023TexasGFAP + NfL

Defense withdrew "no injury" argument after biomarker evidence.

$975K

Settlement

7.8x from $125K

2023TexasAPOE ε4/ε4

APOE genotyping doubled the initial demand by proving heightened vulnerability.

$850K

Settlement

2.1x from $400K

2025Texas (Bexar County)GFAP + NfL + p-Tau 217

Largest TBI-related award in Texas history. Full biomarker panel corroborated irreversible damage.

$831M

Verdict

Record

Governance Risk

Why Measurement Changes the Liability Equation

Once exposure and biomarker signals are measured and retained, the dispute shifts from “did it happen?” to “what did you do with the data?”

Measuring without a decision policy

Without NWP

Organizations collect biomarker data but have no action thresholds. Plaintiffs argue: "You had the data and failed to act."

With NWP

NWP builds decision policies into every program — documented thresholds, required actions, escalation pathways, and independent oversight baked in from day one.

Turns raw data into defensible action

Inconsistent application across sites

Without NWP

Testing is ad hoc. Courts question who was tested, when, and why — exposing selection bias and unequal treatment.

With NWP

NWP deploys standardized protocols across every site, with uniform criteria for who gets tested and when. Consistency is the default.

Same protocol, every site, every time

Incomplete or alterable documentation

Without NWP

Gaps in audit trails, missing custody logs, or editable records undermine every result.

With NWP

Immutable digital audit trails, chain-of-custody logs, and versioned reports. Every data point is traceable from draw to courtroom.

Evidence integrity that survives discovery

No governance or independent review

Without NWP

Internal-only oversight invites the appearance of bias. Opposing counsel argues results were managed, not measured.

With NWP

Independent review frameworks and governance structures that demonstrate objectivity to courts, regulators, and opposing experts.

Third-party credibility built into the program

The Courtroom Hinge

Reliability, Fit, and Chain of Custody

The highest-probability dispute points are not about the biomarker number itself. They center on the system that produced it. NWP’s patented protocol addresses every known attack vector.

Assay variability & cross-platform comparability

Timing windows, sampling cadence & exertion confounding

False positives, negatives & classification thresholds

Specimen & data chain-of-custody

Validated clinical use fits the legal question

Shape the Rules Before They Shape Your Case

Whether you need Daubert-ready evidence, policy guidance, or a strategic briefing on how biomarker science is changing litigation and governance, NWP is the partner that operates on both sides of the equation.

Request a Policy Briefing (512) 497-6487